WO2007118986A2 - Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament - Google Patents
Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament Download PDFInfo
- Publication number
- WO2007118986A2 WO2007118986A2 PCT/FR2007/000560 FR2007000560W WO2007118986A2 WO 2007118986 A2 WO2007118986 A2 WO 2007118986A2 FR 2007000560 W FR2007000560 W FR 2007000560W WO 2007118986 A2 WO2007118986 A2 WO 2007118986A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentrate
- immunoglobulins
- fab
- virus
- igg
- Prior art date
Links
- 239000012141 concentrate Substances 0.000 title claims abstract description 65
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 53
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 53
- 229940072221 immunoglobulins Drugs 0.000 title claims abstract description 35
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title claims abstract description 18
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 25
- 241000700605 Viruses Species 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000017854 proteolysis Effects 0.000 claims description 12
- 201000009182 Chikungunya Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 102000057297 Pepsin A Human genes 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 241001502567 Chikungunya virus Species 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 241000710772 Yellow fever virus Species 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 229940051021 yellow-fever virus Drugs 0.000 claims description 4
- 239000000356 contaminant Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 241000710829 Dengue virus group Species 0.000 claims description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 241000608292 Mayaro virus Species 0.000 claims description 2
- 241000710944 O'nyong-nyong virus Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 241000710942 Ross River virus Species 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 230000001143 conditioned effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 description 15
- 208000001490 Dengue Diseases 0.000 description 10
- 241000255925 Diptera Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 208000025729 dengue disease Diseases 0.000 description 8
- 239000013598 vector Substances 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000238421 Arthropoda Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 208000003152 Yellow Fever Diseases 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960002446 octanoic acid Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000256111 Aedes <genus> Species 0.000 description 2
- 241000256118 Aedes aegypti Species 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001493154 Bunyamwera virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000702669 Coltivirus Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021882 Infections and infestations congenital Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940063656 aluminum chloride Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009836 asymptomatic dengue Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018320 severe joint pain Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a novel medicament for the treatment of • arboviruses, namely a concentrate of immunoglobulins and F (ab) '2 and / or Fab fragments specific for said arbovirus and its method of preparation.
- arboviruses are defined by WHO as viruses that persist in nature mainly or largely through biological transmission between susceptible vertebrate hosts, by blood-sucking arthropods; they multiply and cause viremia in the vertebrate, proliferate in the tissues of the arthropod and are transmitted to a new vertebrate by arthropod p 'iqueur after extrinsic incubation period.
- Virus transmission from a viremic host to a female adult mosquito occurs through the blood sucked in during the bite.
- the virus multiplies in the mosquito, it crosses the stomach border of the animal and is found in its salivary glands. Contamination of a healthy man is achieved by the anti-coagulant mosquito saliva released just before the sting into a blood vessel.
- the window during which a person is a viremic host before becoming ill is only a few days old.
- the known arboviruses belong to five families of viruses: - Togaviri & ae, genus Alphavirus, 28 viruses, including Chikungunya, O'Nyong Nyong, Ross River, Sindbis, Maya.ro viruses
- Flaviviridae genus Flavivirus
- 68 viruses including yellow fever virus, dengue fever, Japanese encephalitis, West-NiIe virus, temperate Eurasian tick-borne encephalitis viruses, Kyasianur forest and Omsk haemorrhagic fever - Bunyaviridae, genus Bunyavirus (138 viruses, including Bunyamwera virus), genus Phleboviris
- Nairovirus genus 24 viruses, including Crimean-Congo hemorrhagic fever virus
- 41 viruses not classified Reoviridae genus Orbivirus (69 viruses) and genus Coltivirus (2 viruses) + 6 viruses not classified Rhabdoviridae, genus Vesiculoviris (18 viruses) and genus Lyssavirus (16 viruses) + 36 unclassified viruses.
- Dengue fever is widespread in all tropical and subtropical areas of the world and is the first public health problem posed by arbovirosis. There are four viral serotypes called "Dengue 1, 2, 3, 4", not resulting in cross-protection. Clinically, there are several forms of dengue fever: asymptomatic dengue fever, classical dengue fever (CD) and severe forms including hemorrhagic fever, dengue haemorrhagic fever (DH) and dengue fever with shock syndrome (DSC), which can lead to death, especially in the child. The 4 types of dengue virus can be involved in both DC and DH. The physiopathological mechanisms involved in the genesis of DH are unknown.
- the theory most often used is based on phenomenon of "immunological facilitation": a subject having been infected by one of the four serotypes not being protected against the other three, a second infection, heterologous, could result in a DH.
- the vectors are mosquitoes of the genus Aedes: Aedes aegypti is the major vector, Aedes albopictus plays an important role in rural and peri-urban areas and tolerates well temperate climates.
- the West NiIe virus is now considered to be the most widespread flavivirus after the dengue virus; it affects the man sporadically or epidemic. He has recently distinguished himself by emerging for the first time on the American continent, during an epidemic that occurred in New York ' in 1999 (62 cases including 7 deaths). It then spread widely in the United States, affecting more than 9000 people in 44 states in 2003, including 2866 cases of encephalitis and 264 deaths. The virus had previously been found in various parts of the globe, in Africa, the Middle East, India, and Europe. Mosquitoes are the main vectors of the West NiIe virus, mainly those of the genus Culex. The main hosts of the virus are birds, whether wild or domestic (ducks, pigeons ).
- the West NiIe virus infects humans primarily through the bite of a vector mosquito.
- the infection is characterized by the sudden onset of severe fever after 3 to 6 days of incubation. This fever is accompanied by headache, backache, muscle aches, coughing, swollen neck glands, and often rash, nausea, abdominal pain, diarrhea and symptoms. breathing. In less than 15% of cases, complications occur: meningitis, encephalitis, and rarely hepatitis, pancreatitis or myocarditis.
- the patient recover spontaneously, sometimes with sequelae. But the disease can be fatal in old people, and sometimes in young children.
- Yellow fever (FJ) remains a daunting endemic and a constant threat in Black Africa and intertropical America. It is due to the yellow fever virus. It comes as a hepatonephritis hemorrhagic, yellow fever typhus, beginning with a phase or red phase, remission on day 3, a status phase or stage with yellow jaundice, vomiting, bleeding mainly digestive syndrome renal. Epidemiology is complex because, in natural environments, yellow fever virus is constantly circulating in monkey populations, thanks to simiophilic wild mosquitoes acting as vectors. It is only accidentally, when man comes into contact with such a sylvatic cycle, that the first human cases occur.
- Chikungunya (abbreviated 'CHIK') is transmitted by mosquitoes of the genus Aedes.
- the name is of Bantu origin and signifies: curling, cowering, or curved man's disease because it causes very severe joint pain associated with stiffness, giving the infected patients a very characteristic curved attitude.
- mosquito species several of them are likely to transmit chikungunya, but only Aedes aegypti and Aedes albopictus have so far been identified as epidemic vectors, because of their adaptation to areas of human habitat.
- DHF dengue haemorrhagic fever
- yellow fever etc.
- the incubation of the disease lasts from four to seven days on average.
- the viremia that is to say the period of presence of the virus in the blood and therefore of possible transmission, is spread over about five days.
- the antibodies are then declared. They stay in the blood. Immunity is therefore normally acquired for life.
- a vaccine is available to prevent yellow fever. Vaccination is routine in exposed populations. However, 60 to 80% of the population must be immunized (naturally or after vaccination) to avoid epidemics. The antibodies appear after about ten days. Vaccination is contraindicated in pregnant women and infants under 6 months of age. A vaccine is also used in Europe • against tick-borne encephalitis. It is marketed under the name TICOVAC® (Baxter SA). Phase I and Phase II were conducted in the United States.
- Immunoglobulins specific for hepatitis B or anti-HBs are widely used to protect any unvaccinated person injuring themselves with contaminated material: the newborn HBs positive antigen mother (in this case the injection must be performed immediately after the birth and should be accompanied by initiation of vaccination), the liver transplant patient to avoid reinfection of the graft and the sexual partner of a HBsAg positive antigen subject pending the effectiveness of vaccination.
- These immunoglobulins make it possible to put in place a protection, either before the exposure to the risk, or in the 24 hours which follow the infectious contact (accidental puncture).
- the Applicant has sought to develop a medicament for treating or preventing arboviroses based on specific immunoglobulins which rapidly immunize exposed people.
- the Applicant has surprisingly shown that such a treatment requires the combination of immunoglobulins and F (ab) '2 and / or Fab fragments specific for the arbovirus to be treated to be effective. 5
- concentration means a product obtained by elimination of certain constituents.
- An immunoglobulin 0 concentrate is obtained by removing certain components of the plasma to an immunoglobulin enriched plasma fraction.
- immunoglobulin refers to a natural globulin which is predominantly present in plasma and has antibody functions and can be used for curative or preventive purposes.
- Immunoglobulins are heterodimers consisting of 2 heavy chains and 2 light chains, linked together by disulfide bridges. Each chain t) v 'is incorporated, position K "-terminal, d r a region' or variable domain (encoded by the rearranged genes V-
- Heavy specific for the antigen against which the antibody is directed, and the C-terminal position, 5 of a constant region consisting of a single domain CL for the light chain or 3 domains (CHl, CH2, and CH3) for the heavy chain.
- the combination of the variable domains and the CH1 and CL domains of the heavy and light chains forms the Fab parts, which are connected to the Fc region by a very flexible hinge region allowing each Fab to bind to its antigenic target while the Fc region, mediator of the effector properties of the antibody, remains accessible to effector molecules such as Fc ⁇ R receptors and CIq.
- IgG is the most abundant immunoglobulin
- immunoglobulins G cross the placenta and, as a result, cause passive immunity in the fetus.
- IgA is found mainly in secretions such as saliva, intestinal juice, sweat and breast milk.
- the essential role of immunoglobulins. A is to prevent pathogens bind to the cell and more specifically to de- cells " 'recouvré ⁇ rté nt ⁇ m-s ⁇ itu-ant; .->.
- IgM are immunoglobulins secreted during the first contact of the body with an antigen. This is the first class of immunoglobulin released by plasma cells. The presence of IgM in the blood indicates an ongoing infection.
- fragment Fab Frametic Antigen Binding
- Fc fragment Antigen Binding
- an F (ab ') 2 fragment is generated, where the two Fab fragments remain bound by two disulfide bridges, and the Fc fragment is cleaved into several peptides.
- the F (ab ') 2 fragment is formed of two Fab' fragments (an Fab 'fragment consisting of an Fab and a hinge region), linked by interchain disulfide bridges to form an F (ab') 2.
- chromatography A method of separating the constituents of a mixture based on their selective adsorption by a suitable support is called "chromatography".
- the invention relates to a concentrate of immunoglobulins and F (ab) '2 and / or Fab fragments specific for an arbovirus as a medicament.
- Such F (ab) '2 or Fab fragments which contain the binding site of the antibody, may have lost a number of -properties of the whole antibody
- the arbovirus in question that can be treated with a concentrate according to the invention can be, for example, one of the dengue viruses, the fever virus
- the concentrate according to the invention is a concentrate of immunoglobulins A, G, and M and fragments F (ab) '2 and / or Fab specific for an arbovirus.
- the concentrate according to the invention is a concentrate of immunoglobulin G exclusively or an immunoglobulin M concentrate exclusively, and F (ab) '2 and / or Fab fragments specific for an arbovirus.
- concentrate according to the invention consists of a concentrate of immunoglobulin G exclusively and fragments F (ab) '2 and / or Fab of IgG and IgM specific for an arbovirus.
- the concentrate according to the invention contains at least 50% of immunoglobulins of IgG type, and 90 to 98% of proteins reacting with antibodies specifically directed against human immunoglobulins, in particular 5 to 50% of F ( ab) 2 and / or Fab, in particular at least 50 to 60 g / l Ig and fragments for a pharmaceutical preparation.
- the concentrate according to the invention may be supplemented with 1 to 10 mmol of magnesium and / or zinc.
- Another object of the invention is the use of a concentrate according to the invention, for the manufacture of a medicament for the treatment of said arbovirus.
- This treatment is prophylactic and / or curative. It can either transfer passive immunity to people who have not yet been affected in an epidemic region, or treat patients already affected by the virus.
- the drug is administered topically, orally, mucosally, intramuscularly or intravenously. Its effectiveness lasts several tens of days, about 21 days, period beyond which the administration must be repeated if the epidemic or the symptoms persist.
- the invention also relates to a method for preparing a concentrate according to the invention. The method comprises mixing an arbovirus specific immunoglobulin concentrate and a specific immunoglobulin concentrate of the same proteolytically modified arbovirus to obtain F (ab) '2 and Fab fragments specific for that arbovirus. This process therefore requires the preparation of at least one immunoglobulin concentrate. This method begins with the formation of a lot 'of at least 1000 plasma donations, each donation having a sufficient titer of Ig directed against said arbovirus.
- a serum having a sufficient titre corresponds, for example, to a serum remaining positive for the detection of anti-Chikungunya antibodies, after having been diluted to 1/1000 , when the titre is measured by an Elisa type method. These donations come from people who have been in contact with the disease, or even from patients who have developed the disease.
- the assay can be performed according to C. van de Water et al., Journal of Immunological Methods, 166 (1993), 157-164.
- lipid and protein contaminants are precipitated in a single step.
- This purification by precipitation in a single stage can take place by diluting the plasma under the conditions of the precipitation according Steinbuch (Steinbuch M., Archiv. Biochem. Biophys.., 134, 279-284) and adding the acid are caprylic. It can also be obtained by the addition of precipitation agents such as, for example, Rivanol, aluminum chloride, cetylpyridinium chloride, octanoic acid, polyphosphates and in the presence of adsorption agents. such as, for example, tricalcium phosphate, bentonite.
- the supernatant resulting from precipitation can constitute a concentrate of immunoglobulins. It then contains a mixture of IgG, A and M. This supernatant is recovered, for example by filtration, possibly by adding at least one filter aid.
- the supernatant resulting from centrifugation or filtration may undergo a viral inactivation treatment, for example a conventional solvent / detergent viral inactivation treatment (Triton X100). If the precipitation carried out was a "typical" precipitation as described above, the caprylic acid residues in the supernatant are removed by PO4 calcium.
- a viral inactivation treatment for example a conventional solvent / detergent viral inactivation treatment (Triton X100). If the precipitation carried out was a "typical" precipitation as described above, the caprylic acid residues in the supernatant are removed by PO4 calcium.
- patent EP1385886 can be applied, in particular the protocols relating to the adjustment of the pH, to the adsorption on a pre-equilibrated column, to the adsorption of the supernatant containing immunoglobulins and accompanying proteins on the column, washing of the column and sequential elution of different classes of immunoglobulins, for example IgG, A or M.
- the supernatant then undergoes an additional purification step by chromatography on an anion exchanger performed at alkaline pH.
- the pH of the supernatant is adjusted beforehand to a pH of from 8.9 to 9.1 and the column was balanced with a buffer having a pH ranging from 8.9 to 9.1.
- the chromatography step allows the adsorption of immunoglobulins on the column and the passage of unadsorbed proteins in the effluent.
- the chromatography may be carried out, for example, on a crosslinked polysaccharide gel or on a vinyl polymer on which DEAE, TMAE or QAE groups have been grafted.
- the immunoglobulins G are eluted with phosphate buffer at pH ranging from pH 4 to 7, preferably at pH 6.2. Subsequent elution with the same phosphate buffer supplemented with 100 to 175 mM NaCl, preferably 150 mM, at a pH ranging from pH 6 to 6.3, makes it possible to collect the IgA. Subsequent elution with the same adjusted buffer having a pH of from 6 to 7 and addition of 250 to 350 mM NaCl, preferably 300 mM, elutes the IgM.
- the immunoglobulins thus eluted and harvested can be concentrated by ultrafiltration and subjected, for example, to conventional sterilizing filtration and then to filtration through nanometric filters of decreasing porosity of 100 to 15 nanometers.
- the concentrated and filtered immunoglobulin solution is added with a pharmaceutically acceptable stabilizing agent such as those described in patent application WO 2004/091656, and this solution is then packaged as a sterile solution and optionally frozen and / or freeze-dried.
- a pharmaceutically acceptable stabilizing agent such as those described in patent application WO 2004/091656, and this solution is then packaged as a sterile solution and optionally frozen and / or freeze-dried.
- nanofiltration makes it possible to eliminate viruses that are resistant to viral inactivation treatment by solvent / detergent.
- the Ig concentrate and the mixture of fragments resulting from the proteolysis are then mixed.
- a concentrate of IgG and F (ab) '2 and / or Fab of IgG and IgM is obtained by: (1) preparing an IgG concentrate as previously described,
- the proteolysis is carried out with 1% of papain, the percentage corresponding to the weight of papain relative to the total weight of proteins of the concentrate.
- proteolysis of immunoglobulins G, A and / or M can also be carried out using plasmin and / or trypsin, proteases whose mode of implementation is well known to those skilled in the art.
- One liter of plasma rich in anti-Chikungunya antibodies is collected from volunteer donors recently infected with Chikungunya virus and cured symptoms of the disease.
- the antibody titer is determined by a method 'Elisa consists in attaching virus antigens on a microtiter plate and then revealing the specific antibodies using a horseradish peroxidase labeled anti-immunoglobulin reagent.
- the samples that have displayed a positive test at a dilution of at least 1/1000 are retained in the context of a "specific" type Elisa method.
- the plasma pool resulting from step 1.1 is cooled to -3 ° C. and added during the cooling of a volume of ethanol sufficient to obtain a final concentration of ethanol of 8%.
- the precipitate formed is removed.
- the pH of the supernatant is then adjusted to pH 5.9 by adding acetate buffer, for example, cooled to -5 ° C., and supplemented with a volume of ethanol sufficient to obtain a final concentration of ethanol of 19%.
- the precipitate formed is collected by centrifugation, for example, and redissolved in an acetate buffer, for example, so as to obtain a pH value of 4.7 to 4.9.
- Octanoic acid is then added at 20 ° C., with vigorous stirring, until a final octanoic acid concentration of 20 g / l is obtained.
- the precipitate formed is separated by centrifugation or alluvial filtration and removed. Tricalcium phosphate or activated charcoal is added to the supernatant, and the mixture is clarified by deep filtration.
- the supernatant resulting from the clarification and containing the immunoglobulins is adjusted to pH 9 by the addition of a NaOH / glycine buffer, for example, and applied on an anion exchange column.
- Equilibration buffer washing is carried out until a DO ' at 280 nm is obtained at the column outlet close to the OD 280 measured during the establishment of the baseline.
- Elution Ig 'G is then carried through a first Sodium phosphate buffer at pH 6.2.
- a second elution is carried out with a phosphate buffer supplemented with 300 mM NaCl.
- the corresponding eluate contains a portion of the Ig G4, Ig A and Ig M.
- the detailed procedure for this purification is found in EP 1385886.
- the pH of the concentrated mixture is adjusted by diafiltration against a buffer • citrate pH 3.8 to 4.2, reaching an acid pH in this range.
- the solution is then supplemented with pepsin (10,000 FlP / mg) so that the amount of pepsin is 1% of the total amount of the proteins contained in the concentrated mixture.
- pepsin 10,000 FlP / mg
- This solution is then sterile filtered to 0.2 ⁇ m and incubated at 37 ° C. for 20 hours.
- the proteolysate is neutralized, for example by the addition of sodium hydroxide, at pH 6.2 +/- 0.2. Diafiltration of the neutralized proteolysate is performed against a glycine buffer at pH 6.2 +/- 0.2, until an OD280 of about 0.005 is obtained, the OD 2S o being measured on the filtrate line of the membrane with a cutoff threshold of 30 kD or less.
- Peptides resulting from pepsin proteolysis and having a size less than or equal to 30 kD are removed during passage over the cut-off membrane.
- the proteolysate obtained therefore contains Fab fragments, F (ab) ' 2 type fragments, but proves to be devoid of Fc type fragments.
- the resulting proteolysate is then mixed with the remaining 75% of the first IgG-containing eluate.
- the mixture is subsequently concentrated by ultrafiltration to reach a final concentration ranging from 50 to 160 g / l, depending on the selected mode of administration.
- the concentrate is titrated according to the method described in Edelman, R. et al. (American Journal of Tropical Medicine and Hygiene, 62 (6), 2000, pp. 681-685).
- the anti-Chikungunya specific antibody titre of the concentrate thus obtained is at least 3 to 10 times higher than that of the starting plasma.
- the concentrate resulting from step 1.3 is stabilized by mixing with a formulation comprising pharmaceutically acceptable excipients, such as, for example, glycine at a final concentration of 0.22M, or such as those described in WO 200 / 091,656.
- a formulation comprising pharmaceutically acceptable excipients, such as, for example, glycine at a final concentration of 0.22M, or such as those described in WO 200 / 091,656.
- the pH of the formulation added to the concentrate is compatible with obtaining a liquid mixture having a pH ranging from 4.2 to 5.6.
- the administration of the resulting liquid mixture can be carried out, for example, intravenously, subcutaneously or intramuscularly, depending on the phlebological state of the recipient.
- the dose administered is 0.2 to 0.8 ml / kg and may, in the event of an epidemic, be administered preventively every 3 weeks to particularly exposed persons, for example the elderly, pregnant women or newborns. .
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0709452-3A BRPI0709452A2 (pt) | 2006-03-31 | 2007-04-02 | concetrado de imunoglobulinas e fragmentos f(ab)' 2 e/ou fab especìficos de um arbovìrus como um produto medicinal |
EP07731238A EP2004229A2 (fr) | 2006-03-31 | 2007-04-02 | Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament |
JP2009502154A JP2009531400A (ja) | 2006-03-31 | 2007-04-02 | 医薬品としての、免疫グロブリンとアルボウイルスに特異性を示すF(ab)’2及び/又はFabフラグメントの濃縮物、濃縮物の利用、及び濃縮物を調整する方法 |
US11/912,444 US7771725B2 (en) | 2006-03-31 | 2007-04-02 | Medicinal concentrate of arbovirus specific immunoglobulins and F(ab)'2 and/or Fab fragments |
AU2007239414A AU2007239414A1 (en) | 2006-03-31 | 2007-04-02 | Concentrate of immunoglobulins and F(ab)'2 and/or Fab fragments specific of an arbovirus as medicine |
CA002647504A CA2647504A1 (fr) | 2006-03-31 | 2007-04-02 | Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament |
IL193820A IL193820A0 (en) | 2006-03-31 | 2008-09-01 | Concentrate of immunoglobulins and f(ab)2 and/or fab fragments specific of an arbovirus as medicine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0602803A FR2899112B1 (fr) | 2006-03-31 | 2006-03-31 | Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament. |
FR0602803 | 2006-03-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007118986A2 true WO2007118986A2 (fr) | 2007-10-25 |
WO2007118986A3 WO2007118986A3 (fr) | 2007-12-06 |
WO2007118986A8 WO2007118986A8 (fr) | 2010-09-10 |
Family
ID=37441009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/000560 WO2007118986A2 (fr) | 2006-03-31 | 2007-04-02 | Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament |
Country Status (11)
Country | Link |
---|---|
US (1) | US7771725B2 (fr) |
EP (1) | EP2004229A2 (fr) |
JP (1) | JP2009531400A (fr) |
KR (1) | KR20080110828A (fr) |
CN (1) | CN101410136A (fr) |
AU (1) | AU2007239414A1 (fr) |
CA (1) | CA2647504A1 (fr) |
FR (1) | FR2899112B1 (fr) |
IL (1) | IL193820A0 (fr) |
TW (1) | TW200904472A (fr) |
WO (1) | WO2007118986A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2374816A1 (fr) | 2010-04-07 | 2011-10-12 | Humalys | Molécules liant le virus du Chikungunya et leurs utilisations |
US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2899111B1 (fr) * | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. |
GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
AR125373A1 (es) * | 2021-04-19 | 2023-07-12 | Bharat Serums & Vaccines Ltd | ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048147A2 (fr) | 2000-12-15 | 2002-06-20 | Glaxo Group Limited | Composes therapeutiques |
FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
-
2006
- 2006-03-31 FR FR0602803A patent/FR2899112B1/fr not_active Expired - Fee Related
-
2007
- 2007-04-02 EP EP07731238A patent/EP2004229A2/fr not_active Withdrawn
- 2007-04-02 CA CA002647504A patent/CA2647504A1/fr not_active Abandoned
- 2007-04-02 WO PCT/FR2007/000560 patent/WO2007118986A2/fr active Application Filing
- 2007-04-02 KR KR1020087025391A patent/KR20080110828A/ko not_active Application Discontinuation
- 2007-04-02 AU AU2007239414A patent/AU2007239414A1/en not_active Abandoned
- 2007-04-02 US US11/912,444 patent/US7771725B2/en not_active Expired - Fee Related
- 2007-04-02 JP JP2009502154A patent/JP2009531400A/ja active Pending
- 2007-04-02 CN CNA2007800110781A patent/CN101410136A/zh active Pending
- 2007-07-23 TW TW096126734A patent/TW200904472A/zh unknown
-
2008
- 2008-09-01 IL IL193820A patent/IL193820A0/en unknown
Non-Patent Citations (7)
Title |
---|
AGRAWAL AMY GUILLET ET AL: "Human immunoglobulin as a treatment for West Nile virus infection" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 188, no. 1, 1 juillet 2003 (2003-07-01), pages 1-4, XP002335078 ISSN: 0022-1899 * |
BAYRY JAGADEESH ET AL: "Intravenous immunoglobulin for infectious diseases: tailor-made or universal?" THE JOURNAL OF INFECTIOUS DISEASES. 15 NOV 2003, vol. 188, no. 10, 15 novembre 2003 (2003-11-15), pages 1610; author reply 1610-1611, XP002409713 ISSN: 0022-1899 * |
BEN-NATHAN D ET AL: "PROPHYLACTIC AND THERAPEUTIC EFFICACY OF HUMAN INTRAVENOUS IMMUNOGLOBULIN IN TREATING WEST NILE VIRUS INFECTION IN MICE" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 188, no. 1, 1 juillet 2003 (2003-07-01), pages 5-12, XP009069705 ISSN: 0022-1899 * |
HAMDAN A ET AL: "POSSIBLE BENEFIT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN A LUNG TRANSPLANT RECIPIENT WITH WEST NILE VIRUS ENCEPHALITIS" TRANSPLANT INFECTIOUS DISEASE, MUNKSGAARD, COPENHAGEN, DK, vol. 4, no. 3, septembre 2002 (2002-09), pages 160-162, XP009069702 ISSN: 1398-2273 * |
KREIL T R ET AL: "Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model." JOURNAL OF VIROLOGY. APR 1997, vol. 71, no. 4, avril 1997 (1997-04), pages 2921-2927, XP002409714 ISSN: 0022-538X * |
KUNISHIGE M ET AL: "Preferential gray matter involvement in dengue myelitis." NEUROLOGY. 23 NOV 2004, vol. 63, no. 10, 23 novembre 2004 (2004-11-23), pages 1980-1981, XP002409715 ISSN: 1526-632X * |
SHIMONI Z ET AL: "TREATMENT OF WEST NILE VIRUS ENCEPHALITIS WITH INTRAVENOUS IMMUNOGLOBULIN" EMERGING INFECTIOUS DISEASES, EID, ATLANTA, GA, US, vol. 7, no. 4, juillet 2001 (2001-07), page 759, XP009069707 ISSN: 1080-6040 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2374816A1 (fr) | 2010-04-07 | 2011-10-12 | Humalys | Molécules liant le virus du Chikungunya et leurs utilisations |
US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
US9738704B2 (en) | 2010-04-07 | 2017-08-22 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2647504A1 (fr) | 2007-10-25 |
FR2899112A1 (fr) | 2007-10-05 |
FR2899112B1 (fr) | 2010-09-03 |
US20090041780A1 (en) | 2009-02-12 |
US7771725B2 (en) | 2010-08-10 |
EP2004229A2 (fr) | 2008-12-24 |
CN101410136A (zh) | 2009-04-15 |
IL193820A0 (en) | 2011-08-01 |
WO2007118986A8 (fr) | 2010-09-10 |
KR20080110828A (ko) | 2008-12-19 |
AU2007239414A1 (en) | 2007-10-25 |
JP2009531400A (ja) | 2009-09-03 |
TW200904472A (en) | 2009-02-01 |
WO2007118986A3 (fr) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9243056B2 (en) | Process for preparing an immunoglobulin composition | |
EP2004229A2 (fr) | Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament | |
PL216741B1 (pl) | Zastosowanie poliklonalnego koziego przeciwciała anty-HLA klasy II | |
CA1090701A (fr) | Medicament permettant de traiter les infections aigues ou chroniques dues au virus de l'hepatite b | |
Guidlolin et al. | Polyvalent horse F (Ab) 2 snake antivenom: Development of process to produce polyvalent horse F (Ab) 2 antibodies anti-african snake venom | |
WO2007118987A1 (fr) | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament | |
JPH09124507A (ja) | ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 | |
EP1320552B1 (fr) | Procede de production d'immunoglobulines anti-thymocytes humains | |
US6200565B1 (en) | Oral administration of immunoglobulins for treating autoimmune hearing loss | |
BRPI0709452A2 (pt) | concetrado de imunoglobulinas e fragmentos f(ab)' 2 e/ou fab especìficos de um arbovìrus como um produto medicinal | |
EP0374053B1 (fr) | Médicament pour le traitement ou la prévention par immunisation passive de l'infection par le virus HIV et procédés de préparation | |
TW200904468A (en) | Concentrate of chikungunya-specific immunoglobulins as a medical product | |
WO1986005099A1 (fr) | Preparations d'immunoglobulines presentant des titres eleves en anticorps bloquants | |
FR2734160A1 (fr) | Utilisation d'un compose comportant une structure glycanique pour le blocage d'anticorps et procede d'obtention d'un tel produit | |
CA2423805A1 (fr) | Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma enrichies en immunoglobuline g | |
JPH11504636A (ja) | レトロウイルスと腫瘍成長を阻害するための血清調製物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07731238 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11912444 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7392/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193820 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007239414 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009502154 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2007239414 Country of ref document: AU Date of ref document: 20070402 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780011078.1 Country of ref document: CN Ref document number: 2647504 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007731238 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087025391 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0709452 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080930 |